Our interdisciplinary laboratory aims to better understand liver fibrosis and identify novel therapeutic targets for the advanced stages of chronic liver disease (CLD), which include cirrhosis and portal hypertension, focusing on mechanobiology. We conduct translational research that integrates in vivo and in vitro approaches. We employ comprehensive preclinical pipelines using established and genetically engineered rodent models, including MASH, fibrosis, and cirrhosis models, to assess drug efficacy and study disease progression. Through targeted genetic modifications, we investigate cellular crosstalk among endothelial, immune, and hepatic stellate cells to identify drivers of fibrogenesis and fibrosis resolution.
In parallel, we deploy in vitro systems using 2D and 3D culture platforms to recapitulate hepatic microenvironments and study the mechanobiology of hepatic sinusoid dysfunction. Our models enable high-content screening of cellular, molecular, and functional endpoints using omics and imaging technologies.
We combine automated experimental platforms with nanomedicine approaches to investigate how novel therapies, including targeted nanodrug delivery, modulate extracellular matrix remodeling, intrahepatic vascular resistance, and cellular signaling. Our research aims to inform the design of next-generation therapeutics for cirrhosis and portal hypertension, and advances the understanding of the pathophysiology of CLD.
